These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

98 related articles for article (PubMed ID: 2019851)

  • 1. Failure of oral administration of single rising doses of bromocriptine to produce acute anti-Parkinsonian effects.
    Poewe W; Schelosky L; Kleedorfer B
    J Neurol Neurosurg Psychiatry; 1991 Feb; 54(2):186-7. PubMed ID: 2019851
    [No Abstract]   [Full Text] [Related]  

  • 2. Efficacy and tolerability of tolcapone compared with bromocriptine in levodopa-treated parkinsonian patients. Tolcapone Study Group.
    Mov Disord; 1999 Jan; 14(1):38-44. PubMed ID: 9918342
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The Sydney Multicentre Study of Parkinson's disease: a report on the first 3 years.
    Hely MA; Morris JG; Rail D; Reid WG; O'Sullivan DJ; Williamson PM; Genge S; Broe GA
    J Neurol Neurosurg Psychiatry; 1989 Mar; 52(3):324-8. PubMed ID: 2647907
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Bromocriptine and levodopa in early combination in Parkinson's disease: first results of the Collaborative European Multicentric Trial.
    Olsson JE
    Adv Neurol; 1990; 53():421-3. PubMed ID: 2239483
    [No Abstract]   [Full Text] [Related]  

  • 5. Long term bromocriptine treatment in de novo parkinsonian patients.
    Herskovits E; Yorio A; Leston J
    Medicina (B Aires); 1988; 48(4):345-50. PubMed ID: 3076200
    [No Abstract]   [Full Text] [Related]  

  • 6. Parkinsonian medication one hour before meals improves symptomatic swallowing: a case study.
    Fonda D; Schwarz J; Clinnick S
    Dysphagia; 1995; 10(3):165-6. PubMed ID: 7614856
    [No Abstract]   [Full Text] [Related]  

  • 7. [Comparison of administration of low doses of bromocriptine and levodopa in the early treatment of Parkinson disease].
    Sternić N; Kostić V
    Srp Arh Celok Lek; 1992; 120(1-2):1-5. PubMed ID: 1641693
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Bromocriptine: long-term low-dose therapy in Parkinson's disease.
    Teychenne PF; Bergsrud D; Elton RL; Racy A
    Clin Neuropharmacol; 1986; 9(2):138-45. PubMed ID: 3708599
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A nationwide collaborative study on the long-term effects of bromocriptine in patients with Parkinson's disease. The fourth interim report.
    Nakanishi T; Mizuno Y; Goto I; Iwata M; Kanazawa I; Kowa H; Mannen T; Nishitani H; Ogawa N; Takahashi A
    Eur Neurol; 1991; 31 Suppl 1():3-16. PubMed ID: 1906808
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Seven-year follow-up study of bromocriptine therapy for Parkinson's disease.
    Yanagisawa N; Kanazawa I; Goto I; Kowa H; Kuno S; Mizuno Y; Tashiro K; Ogawa N
    Eur Neurol; 1994; 34 Suppl 3():29-35. PubMed ID: 7821333
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Subcutaneous apomorphine for parkinsonian patients with psychiatric side effects on oral treatment.
    Ray-Chaudhuri K; Abbott RJ; Millac PA
    J Neurol Neurosurg Psychiatry; 1991 Apr; 54(4):372-3. PubMed ID: 2056329
    [No Abstract]   [Full Text] [Related]  

  • 12. Parlodel SRO in Parkinson's disease: a double-blind randomized comparison of Parlodel standard and Parlodel SRO.
    Jansen EN; Staal-Schreinemachers A; van der Sande JJ; Haas JA; Lakke JP
    Eur Neurol; 1992; 32(6):318-20. PubMed ID: 1490497
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Clinical significance of long-term treatment of L-dopa with bromocriptine in parkinsonian patients who showed declining efficacy during L-dopa therapy].
    Indo T
    Nihon Naika Gakkai Zasshi; 1985 Mar; 74(3):297-306. PubMed ID: 4009013
    [No Abstract]   [Full Text] [Related]  

  • 14. Low-dose bromocriptine in the early phases of Parkinson's disease.
    Tolosa E; Blesa R; Bayes A; Forcadell F
    Clin Neuropharmacol; 1987 Apr; 10(2):168-74. PubMed ID: 3332610
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Clinical administration of parlodel in low doses.
    Lipcsey A; Peres A
    Adv Neurol; 1984; 40():557-61. PubMed ID: 6695636
    [No Abstract]   [Full Text] [Related]  

  • 16. [Improved therapeutic response to L-dopa in Parkinson's disease, when combined with bromocriptine (author's transl)].
    Ulm G
    Nervenarzt; 1981 Feb; 52(2):116-20. PubMed ID: 7219619
    [No Abstract]   [Full Text] [Related]  

  • 17. Adjunctive therapy with bromocriptine in Parkinson's disease.
    Temlett JA; Ming A; Saling M; Fritz VU; Blumenfeld A; Bilchik TR; Becker AL; Fourie PB; Reef HE
    S Afr Med J; 1990 Dec; 78(11):680-5. PubMed ID: 2251616
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Severe evening dyskinesias in advanced Parkinson's disease: clinical description, relation to plasma levodopa, and treatment.
    Zimmerman TR; Sage JI; Lang AE; Mark MH
    Mov Disord; 1994 Mar; 9(2):173-7. PubMed ID: 8196678
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Bromocriptine: problems with low-dose de novo therapy in Parkinson's disease.
    Grimes JD; Delgado MR
    Clin Neuropharmacol; 1985; 8(1):73-7. PubMed ID: 3978651
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Third interim report of the nationwide collaborative study on the long-term effects of bromocriptine in the treatment of parkinsonian patients.
    Nakanishi T; Kanazawa I; Goto I; Iwata M; Kowa H; Mannen T; Mizuno Y; Nishitani H; Ogawa N; Takahashi A
    Eur Neurol; 1990; 30 Suppl 1():3-8. PubMed ID: 2178938
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.